E

Editas Medicine
D

EDIT

2.57000
USD
0.02
(0.78%)
مغلق
حجم التداول
43,243
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
215,142,048
أصول ذات صلة
ALNY
ALNY
-4.39
(-1.33%)
325.26 USD
B
BEAM
0.060
(0.30%)
19.950 USD
C
CRSP
0.455
(0.88%)
52.120 USD
N
NTLA
-0.020
(-0.19%)
10.710 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
S
SRPT
0.010
(0.06%)
18.200 USD
TMO
TMO
1.69
(0.40%)
429.33 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.